Rapid Influenza Diagnostic Tests (RIDT) Market Size by End-use (Hospitals, Diagnostics Centers, Research Laboratories), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022

Description

List of Tables

The rapid influenza diagnostic tests (RIDT) market is expected to grow significantly by 2030 owing to increasing prevalence of influenza. In addition, surging necessity for early diagnosis, along with rising popularity of rapid testing, is set to further boost market growth through the forecast period.

Notably, lack of skilled professionals and stringent lockdown regulations imposed during the COVID-19 outbreak posed a threat to market growth However, with the burgeoning number of cases and high risk of exposure to COVID-19 in hospital settings, at-home testing gained massive popularity. Thus, rising consumer interest in at-home testing kits, coupled with soaring demand for telemedicine for influenza infection diagnosis, has positively impacted the product landscape of the rapid influenza diagnostic tests (RIDT) market.

Furthermore, major players in the industry have been focusing on research and development activities to introduce technologically advanced rapid influenza tests. In addition, strategic partnerships and acquisitions have also aided in business expansion.

For instance, in October 2020, Quidel Corporation, a leading manufacturer of diagnostic healthcare products, received EUA (Emergency Use Authorization) from the U.S. FDA (Food and Drug Administration) for marketing its Sofia 2 Flu + SARS Antigen FIA, a rapid point-of-care test used in conjunction with Sofia 2 Fluorescent Immunoassay Analyzer to differentiate nucleocapsid protein antigen from SARS-CoV-2 and influenza A and B via direct nasal (NS) and nasopharyngeal (NP) swab samples in potential COVID-19 patients.

To cite another instance, in March 2021, Abbott, a multinational medical and healthcare devices company, introduced its Alinity m Resp-4-Plex assay that detects COVID-19, influenza A, influenza B, and RSV using only one swab. The innovation, which has received U.S. FDA Emergency Use Authorization, aims to reduce discomfort, and give an efficient four-in-one assay for quick diagnosis.

In another instance, in January 2021, Thermo Fisher Scientific, a prominent supplier in the rapid influenza diagnostic tests (RIDT) market, announced its plans to takeover molecular diagnostic expert Mesa Biotech. Mesa provides gold-standard nucleic acid PCR (polymerase chain reaction) amplification to point-of-care diagnostics for COVID-19, RSV, Influenza A and B, and Strep A.

The rapid influenza diagnostic tests (RIDT) market has been bifurcated in terms of end-use and region. Based on end-use, the RIDT market has been divided into research laboratories, hospitals, diagnostic centers, and others. In 2021, the hospitals segment accounted for over $272 million in revenue and is poised to register substantial gains by 2030. Several factors, including the availability of board-certified skilled doctors, high success rate, faster & more efficient work, and so forth, are slated to fuel segmental growth in the forthcoming years.

In the regional landscape, the Latin America rapid influenza diagnostic tests (RIDT) market garnered a valuation of approximately $82 million in 2021 and is anticipated to grow at a CAGR of over 7.5% through the forecast timeline. Rising prevalence of influenza and growing awareness about influenza infection in countries across the region are likely to support LATAM market expansion in the future.

Product Code: 4329

Chapter 1 Methodology

1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 Rapid influenza diagnostic tests industry 360 degree synopsis, 2017 - 2030
- 2.1.1 Business trends
- 2.1.2 End-use trends
- 2.1.3 Regional Trends

Chapter 3 Rapid Influenza Diagnostic Tests Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030 (USD Million)
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Growing prevalence of influenza
  - 3.3.1.2 Technological advancements
  - 3.3.1.3 Rising demand for early diagnosis and control of influenza
  - 3.3.1.4 Increasing popularity of rapid diagnostic tests
  - 3.3.1.5 Diagnostic advantages in influenza testing
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Lack of skilled professionals
  - 3.3.2.2 Stringent regulations
3.4 Growth potential analysis
- 3.4.1 By end-use
3.5 COVID-19 impact analysis
3.6 Porter's analysis
3.7 Competitive landscape, 2021
- 3.7.1 Company matrix analysis, 2021
3.8 PESTEL analysis

Chapter 4 Rapid Influenza Diagnostic Tests Market, By End-use

4.1 Key segment trends
4.2 Hospitals
- 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Diagnostics centers,
- 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.4 Research laboratories
- 4.4.1 Market size, by region, 2017 - 2030 (USD Million)
4.5 Others
- 4.5.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 5 Rapid Influenza Diagnostic Tests Market, By Region

5.1 Key regional trends
5.2 North America
- 5.2.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.2.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.2.3 U.S.
  - 5.2.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.2.4 Canada
  - 5.2.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.3 Europe
- 5.3.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.3.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.3.3 Germany
  - 5.3.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.3.4 UK
  - 5.3.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.3.5 France
  - 5.3.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.3.6 Italy
  - 5.3.6.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.3.7 Spain
  - 5.3.7.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.4 Asia Pacific
- 5.4.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.4.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.4.3 China
  - 5.4.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.4.4 Japan
  - 5.4.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.4.5 India
  - 5.4.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.4.6 Australia
  - 5.4.6.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.4.7 South Korea
  - 5.4.7.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.5 Latin America
- 5.5.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.5.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.5.3 Brazil
  - 5.5.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.5.4 Mexico
  - 5.5.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.5.5 Argentina
  - 5.5.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.6 Middle East & Africa
- 5.6.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.6.2 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.6.3 South Africa
  - 5.6.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.6.4 Saudi Arabia
  - 5.6.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
- 5.6.5 UAE
  - 5.6.5.1 Market size, by end-use, 2017 - 2030 (USD Million)

Chapter 6 Company Profiles

6.1 Competitive dashboard, 2021
6.2 F. Hoffmann-La Roche Ltd
- 6.2.1 Business overview
- 6.2.2 Financial data
- 6.2.3 Product landscape
- 6.2.4 Strategic outlook
- 6.2.5 SWOT analysis
6.3 Abbott
- 6.3.1 Business overview
- 6.3.2 Financial data
- 6.3.3 Product landscape
- 6.3.4 Strategic outlook
- 6.3.5 SWOT analysis
6.4 Becton, Dickinson and Company
- 6.4.1 Business overview
- 6.4.2 Financial data
- 6.4.3 Product landscape
- 6.4.4 Strategic outlook
- 6.4.5 SWOT analysis
6.5 Coris BioConcept
- 6.5.1 Business overview
- 6.5.2 Financial data
- 6.5.3 Product landscape
- 6.5.4 Strategic outlook
- 6.5.5 SWOT analysis
6.6 DiaSorin SpA
- 6.6.1 Business overview
- 6.6.2 Financial data
- 6.6.3 Product landscape
- 6.6.4 Strategic outlook
- 6.6.5 SWOT analysis
6.7 Meridian Bioscience Inc.
- 6.7.1 Business overview
- 6.7.2 Financial data
- 6.7.3 Product landscape
- 6.7.4 Strategic outlook
- 6.7.5 SWOT analysis
6.8 Quidel Corporation
- 6.8.1 Business overview
- 6.8.2 Financial data
- 6.8.3 Product landscape
- 6.8.4 Strategic outlook
- 6.8.5 SWOT analysis
6.9 Sekisui Diagnostics
- 6.9.1 Business overview
- 6.9.2 Financial data
- 6.9.3 Product landscape
- 6.9.4 Strategic outlook
- 6.9.5 SWOT analysis
6.10 Thermo Fischer Scientific Inc.
- 6.10.1 Business overview
- 6.10.2 Financial data
- 6.10.3 Product landscape
- 6.10.4 Strategic outlook
- 6.10.5 SWOT analysis
6.11 Hologic Inc.
- 6.11.1 Business overview
- 6.11.2 Financial data
- 6.11.3 Product landscape
- 6.11.4 Strategic outlook
- 6.11.5 SWOT analysis